drugset / Trial / NCT01566162
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
NaSingle-groupOpen-labelTreatment
Summary
This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lurasidone | Small molecule | 40 mg | Oral |
| Subject | Lurasidone | Small molecule | 80 mg | Oral |